The resveratrol analogue, 3,4,5,4'‑trans-tetramethoxystilbene, inhibits the growth of A375 melanoma cells through multiple anticancer modes of action

Androutsopoulos,Vasilis P.; Fragiadaki,Irene; Spandidos,Demetrios A.; Tosca,Androniki

doi:10.3892/ijo.2016.3635

The resveratrol analogue, 3,4,5,4'‑trans-tetramethoxystilbene, inhibits the growth of A375 melanoma cells through multiple anticancer modes of action

Authors:
- Vasilis P. Androutsopoulos
- Irene Fragiadaki
- Demetrios A. Spandidos
- Androniki Tosca
View Affiliations

Affiliations: Laboratory of Experimental Dermatology, University of Crete, Medical School, Heraklion 71003, Greece, Laboratory of Clinical Virology, University of Crete, Medical School, Heraklion 71003, Greece
Published online on: July 28, 2016 https://doi.org/10.3892/ijo.2016.3635
Pages: 1305-1314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol is a natural dietary product that has demonstrated multifaceted anticancer activity. Several analogues of resveratrol have been synthesized in an effort to enhance the pharmacological potency and improve the pharmacokinetic properties of the compound. 3,4,5,4'‑trans‑tetramethoxystilbene (3,4,5,4'‑TMS) is a methoxylated analogue of resveratrol that has demonstrated anti-proliferative activity in vitro (in cancer cell lines) and in vivo (in xenograft models). In the present study, the anticancer effects of 3,4,5,4'‑TMS in A375 human melanoma cells were examined. 3,4,5,4'‑TMS markedly inhibited the proliferation of A375 cells (IC50=0.7 µM), via a mechanism involving mitotic arrest at the prometaphase stage of cell division. This effect was accompanied by the upregulation of the expression of the mitogen activated protein kinases, JNK and p38, and the concomitant activation of p38, that was verified by the nuclear translocation of the phoshorylated form of the protein. The pharmacological inhibition of p38 by SB203580 (4 µM) attenuated the effects of 3,4,5,4'‑TMS, as demonstrated by decreased cell cycle progression at the mitotic phase. Furthermore, 3,4,5,4'‑TMS increased the total levels of Aurora A, while it inhibited the localization of the protein to the spindle poles. Finally, 3,4,5,4'‑TMS exhibited anti-metastatic activity, inhibiting A375 cell migration and the attachment of the cells to a collagen type IV-coated surface. Collectively, the data suggest that 3,4,5,4'‑TMS is an effective chemotherapeutic drug for the treatment of human melanoma and that it exerts its effects through multiple anticancer modes of action.

View Figures

View References

1	Tripp MK, Watson M, Balk SJ, Swetter SM and Gershenwald JE: State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. May 27–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
2	Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and Malaponte G: Melanoma: Molecular pathogenesis and emerging target therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
3	Wong CY, Helm MA, Kalb RE, Helm TN and Zeitouni NC: The presentation, pathology, and current management strategies of cutaneous metastasis. N Am J Med Sci. 5:499–504. 2013. View Article : Google Scholar : PubMed/NCBI
4	Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM and Richardson LC: Centers for Disease Control and Prevention (CDC): Vital signs: Melanoma incidence and mortality trends and projections - United States, 1982–2030. MMWR Morb Mortal Wkly Rep. 64:591–596. 2015.PubMed/NCBI
5	Pal HC, Hunt KM, Diamond A, Elmets CA and Afaq F: Phytochemicals for the management of melanoma. Mini Rev Med Chem. Feb 11–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
6	Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP and Gescher AJ: Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetra-methoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer. 115:194–201. 2005. View Article : Google Scholar : PubMed/NCBI
7	Atten MJ, Attar BM, Milson T and Holian O: Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem Pharmacol. 62:1423–1432. 2001. View Article : Google Scholar : PubMed/NCBI
8	Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
9	Mahyar-Roemer M, Köhler H and Roemer K: Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells. BMC Cancer. 2:272002. View Article : Google Scholar : PubMed/NCBI
10	Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP and Gescher AJ: Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br J Cancer. 90:736–744. 2004. View Article : Google Scholar : PubMed/NCBI
11	Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA and Lavasanifar A: Resveratrol analog trans 3,4,5,4′-tetrame-thoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol. 63:27–35. 2008. View Article : Google Scholar : PubMed/NCBI
12	Androutsopoulos VP, Fragiadaki I and Tosca A: Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4′-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 24:632–634. 2015. View Article : Google Scholar : PubMed/NCBI
13	Androutsopoulos V, Arroo RR, Hall JF, Surichan S and Potter GA: Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism. Breast Cancer Res. 10:R392008. View Article : Google Scholar : PubMed/NCBI
14	Androutsopoulos VP, Ruparelia KC, Papakyriakou A, Filippakis H, Tsatsakis AM and Spandidos DA: Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: Structural requirements for potency. Eur J Med Chem. 46:2586–2595. 2011. View Article : Google Scholar : PubMed/NCBI
15	Piotrowska H, Myszkowski K, Ziółkowska A, Kulcenty K, Wierzchowski M, Kaczmarek M, Murias M, Kwiatkowska-Borowczyk E and Jodynis-Liebert J: Resveratrol analogue 3,4,4′,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol. 263:53–60. 2012. View Article : Google Scholar : PubMed/NCBI
16	Mazué F, Colin D, Gobbo J, Wegner M, Rescifina A, Spatafora C, Fasseur D, Delmas D, Meunier P, Tringali C, et al: Structural determinants of resveratrol for cell proliferation inhibition potency: Experimental and docking studies of new analogs. Eur J Med Chem. 45:2972–2980. 2010. View Article : Google Scholar : PubMed/NCBI
17	Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gossé F, Launay JF, Brouillard R and Raul F: Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer. 107:189–196. 2003. View Article : Google Scholar : PubMed/NCBI
18	Shen CH, Shee JJ, Wu JY, Lin YW, Wu JD and Liu YW: Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 160:2008–2027. 2010. View Article : Google Scholar : PubMed/NCBI
19	Grossman D and Altieri DC: Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 20:3–11. 2001. View Article : Google Scholar
20	Mooney EE, Ruis Peris JM, O’Neill A and Sweeney EC: Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol. 48:242–244. 1995. View Article : Google Scholar : PubMed/NCBI
21	Alotaibi MR, Asnake B, Di X, Beckman MJ, Durrant D, Simoni D, Baruchello R, Lee RM, Schwartz EL and Gewirtz DA: Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death. Biochem Pharmacol. 86:1688–1698. 2013. View Article : Google Scholar : PubMed/NCBI
22	Teng M, Jiang XP, Zhang Q, Zhang JP, Zhang DX, Liang GP and Huang YS: Microtubular stability affects pVHL-mediated regulation of HIF-1alpha via the p38/MAPK pathway in hypoxic cardiomyocytes. PLoS One. 7:e350172012. View Article : Google Scholar : PubMed/NCBI
23	Yang Y, Zhu X, Chen Y, Wang X and Chen R: p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in colchicine-induced cortical neurons apoptosis. Eur J Pharmacol. 576:26–33. 2007. View Article : Google Scholar : PubMed/NCBI
24	Quan H, Xu Y and Lou L: p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer. 122:1730–1737. 2008. View Article : Google Scholar
25	Rohena CC, Peng J, Johnson TA, Crews P and Mooberry SL: Chemically diverse microtubule stabilizing agents initiate distinct mitotic defects and dysregulated expression of key mitotic kinases. Biochem Pharmacol. 85:1104–1114. 2013. View Article : Google Scholar : PubMed/NCBI
26	Aires DJ, Wick J, Shaath TS, Rajpara AN, Patel V, Badawi AH, Li C, Fraga GR, Doolittle G and Liu DY: Economic costs avoided by diagnosing melanoma six months earlier justify >100 benign biopsies. J Drugs Dermatol. 15:527–532. 2016.PubMed/NCBI
27	Roman BI, De Coen LM, Thérèse FC, Mortier S, De Ryck T, Vanhoecke BW, Katritzky AR, Bracke ME and Stevens CV: Design, synthesis and structure-activity relationships of some novel, highly potent anti-invasive (E)- and (Z)-stilbenes. Bioorg Med Chem. 21:5054–5063. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, et al: Phase II trial of combretastatin A4 phosphate, carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 22:2036–2041. 2011. View Article : Google Scholar : PubMed/NCBI
29	Maccario C, Savio M, Ferraro D, Bianchi L, Pizzala R, Pretali L, Forti L and Stivala LA: The resveratrol analog 4,4′-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells. Carcinogenesis. 33:2172–2180. 2012. View Article : Google Scholar : PubMed/NCBI
30	Weng CJ, Wu CF, Huang HW, Wu CH, Ho CT and Yen GC: Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem. 58:2886–2894. 2010. View Article : Google Scholar : PubMed/NCBI
31	Chen LK, Qiang PF, Xu QP, Zhao YH, Dai F and Zhang L: Trans-3,4,5,4′-tetramethoxystilbene, a resveratrol analog, potently inhibits angiogenesis in vitro and in vivo. Acta Pharmacol Sin. 34:1174–1182. 2013. View Article : Google Scholar : PubMed/NCBI
32	Russo A, Ficili B, Candido S, Pezzino FM, Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA and Libra M: Emerging targeted therapies for melanoma treatment (Review). Int J Oncol. 45:516–524. 2014.PubMed/NCBI